adenine has been researched along with Central Nervous System Neoplasm in 30 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amonafide 300 mg/M2 was administered intravenously on a daily x 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors." | 2.70 | Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study. ( Brown, TD; Craig, JB; Jaeckle, K; Rankin, C; Solank, DL; Taylor, SA; Townsend, JJ; Vance, RB, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.33) | 29.6817 |
| 2010's | 14 (46.67) | 24.3611 |
| 2020's | 15 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malfona, F | 1 |
| Testi, AM | 1 |
| Moleti, ML | 1 |
| Petrucci, L | 1 |
| Leccisotti, L | 1 |
| Martelli, M | 1 |
| Di Rocco, A | 1 |
| T Low, J | 1 |
| B Peters, K | 1 |
| Pang, DW | 1 |
| Chen, FL | 1 |
| Li, WY | 1 |
| Lauer, EM | 1 |
| Waterhouse, M | 1 |
| Braig, M | 1 |
| Mutter, J | 1 |
| Bleul, S | 1 |
| Duque-Afonso, J | 1 |
| Duyster, J | 1 |
| Marks, R | 1 |
| Reinacher, PC | 1 |
| Prinz, M | 1 |
| Illerhaus, G | 2 |
| Finke, J | 1 |
| Schorb, E | 2 |
| Scherer, F | 1 |
| Wang, L | 1 |
| Li, X | 1 |
| He, YZ | 1 |
| Lewis, KL | 1 |
| Chin, CK | 1 |
| Manos, K | 1 |
| Casey, J | 1 |
| Hamad, N | 1 |
| Crawford, J | 1 |
| Ho, SJ | 1 |
| Issa, S | 1 |
| Grigg, A | 1 |
| Wood, P | 1 |
| Gandhi, MK | 1 |
| Do, B | 1 |
| Nastoupil, L | 1 |
| Hawkes, EA | 1 |
| Cheah, CY | 1 |
| Jiménez, I | 1 |
| Carabia, J | 1 |
| Bobillo, S | 1 |
| Palacio, C | 1 |
| Abrisqueta, P | 1 |
| Pagès, C | 1 |
| Nieto, JC | 1 |
| Castellví, J | 1 |
| Martínez-Ricarte, F | 1 |
| Escoda, L | 1 |
| Perla, C | 1 |
| Céspedes Torrez, DH | 1 |
| Boix, J | 1 |
| Purroy, N | 1 |
| Puigdefàbregas, L | 1 |
| Seoane, J | 1 |
| Bosch, F | 1 |
| Crespo, M | 1 |
| Chen, F | 1 |
| Pang, D | 1 |
| Guo, H | 1 |
| Ou, Q | 1 |
| Wu, X | 1 |
| Jiang, X | 1 |
| Wei, X | 1 |
| Liu, S | 1 |
| Huang, L | 1 |
| Liang, Z | 1 |
| Zhou, D | 1 |
| Li, W | 1 |
| Okahashi, N | 1 |
| Uchihara, M | 1 |
| Hoshino, E | 1 |
| Bouffard, MA | 1 |
| Chwalisz, BK | 1 |
| Romero, JM | 1 |
| Arrillaga-Romany, IC | 1 |
| Massoth, LR | 1 |
| Renaud, L | 1 |
| Bossard, JB | 1 |
| Carpentier, B | 1 |
| Terriou, L | 1 |
| Cambier, N | 1 |
| Chanteau, G | 1 |
| Escure, G | 1 |
| Tilmont, R | 1 |
| Barbieux, S | 1 |
| Wemeau, M | 1 |
| Hieulle, J | 1 |
| Boyle, EM | 1 |
| Morschhauser, F | 2 |
| Tsilimidos, G | 1 |
| Horisberger, A | 1 |
| Ribi, C | 1 |
| Cairoli, A | 1 |
| Stalder, G | 1 |
| Tanigawa, T | 1 |
| Sakurai, M | 1 |
| Kato, J | 1 |
| Mizuno, K | 1 |
| Fujita, S | 1 |
| Koda, Y | 1 |
| Kikuchi, T | 1 |
| Shimizu, T | 1 |
| Okamoto, S | 1 |
| Kataoka, K | 1 |
| Carella, M | 1 |
| Stefoni, V | 1 |
| Broccoli, A | 1 |
| Argnani, L | 1 |
| Zinzani, PL | 1 |
| Barrette, AM | 1 |
| Bouhaddou, M | 1 |
| Birtwistle, MR | 1 |
| Vitagliano, O | 1 |
| Trastulli, F | 1 |
| Cacace, F | 1 |
| Leone, S | 1 |
| Memoli, M | 1 |
| Scalia, G | 1 |
| Notarangelo, M | 1 |
| Mainolfi, CG | 1 |
| De Renzo, A | 1 |
| Pane, F | 1 |
| Christoforidou, A | 1 |
| Kapsas, G | 1 |
| Bezirgiannidou, Z | 1 |
| Papamichos, S | 1 |
| Kotsianidis, Ι | 1 |
| Kasenda, B | 1 |
| Abid, MB | 1 |
| Stromich, J | 1 |
| Gundacker, ND | 1 |
| Plander, M | 1 |
| Szendrei, T | 1 |
| Vadvári, Á | 1 |
| Iványi, J | 1 |
| Grommes, C | 2 |
| Nayak, L | 1 |
| Tun, HW | 1 |
| Batchelor, TT | 1 |
| Pouzoulet, F | 1 |
| Alentorn, A | 1 |
| Royer-Perron, L | 1 |
| Assayag, F | 1 |
| Mokhtari, K | 1 |
| Labiod, D | 1 |
| Le Garff-Tavernier, M | 1 |
| Daniau, M | 2 |
| Menet, E | 1 |
| Peyre, M | 1 |
| Schnitzler, A | 1 |
| Guegan, J | 1 |
| Davi, F | 1 |
| Hoang-Xuan, K | 3 |
| Soussain, C | 3 |
| Tang, SS | 1 |
| Wolfe, J | 1 |
| Kaley, TJ | 1 |
| Daras, M | 1 |
| Pentsova, EI | 1 |
| Piotrowski, AF | 1 |
| Stone, J | 1 |
| Lin, A | 1 |
| Nolan, CP | 1 |
| Manne, M | 1 |
| Codega, P | 1 |
| Campos, C | 1 |
| Viale, A | 1 |
| Thomas, AA | 1 |
| Berger, MF | 1 |
| Hatzoglou, V | 1 |
| Reiner, AS | 1 |
| Panageas, KS | 1 |
| DeAngelis, LM | 1 |
| Mellinghoff, IK | 1 |
| Choquet, S | 2 |
| Blonski, M | 1 |
| Leclercq, D | 1 |
| Houillier, C | 2 |
| Rezai, K | 1 |
| Bijou, F | 1 |
| Houot, R | 1 |
| Boyle, E | 2 |
| Gressin, R | 1 |
| Nicolas-Virelizier, E | 1 |
| Barrie, M | 1 |
| Moluçon-Chabrot, C | 1 |
| Lelez, ML | 1 |
| Clavert, A | 1 |
| Coisy, S | 1 |
| Leruez, S | 1 |
| Touitou, V | 1 |
| Cassoux, N | 1 |
| Ertault de la Bretonnière, M | 1 |
| El Yamani, A | 1 |
| Ghesquières, H | 1 |
| Bernard, S | 1 |
| Goldwirt, L | 1 |
| Amorim, S | 1 |
| Brice, P | 1 |
| Brière, J | 1 |
| de Kerviler, E | 1 |
| Mourah, S | 1 |
| Sauvageon, H | 1 |
| Thieblemont, C | 1 |
| Tucker, DL | 1 |
| Naylor, G | 1 |
| Kruger, A | 1 |
| Hamilton, MS | 1 |
| Follows, G | 1 |
| Rule, SA | 1 |
| Mason, C | 1 |
| Savona, S | 1 |
| Rini, JN | 1 |
| Castillo, JJ | 1 |
| Xu, L | 1 |
| Hunter, ZR | 1 |
| Treon, SP | 1 |
| Allen, SL | 1 |
| Chamoun, K | 1 |
| Larrieu-Ciron, D | 1 |
| Al Jijakli, A | 1 |
| Delrieu, V | 1 |
| Delwail, V | 1 |
| Ghildiyal, R | 1 |
| Dixit, D | 1 |
| Sen, E | 1 |
| Taylor, SA | 1 |
| Rankin, C | 1 |
| Townsend, JJ | 1 |
| Craig, JB | 1 |
| Vance, RB | 1 |
| Solank, DL | 1 |
| Brown, TD | 1 |
| Jaeckle, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCN[NCT02315326] | Phase 1/Phase 2 | 109 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma[NCT02542514] | Phase 2 | 52 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for adenine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
Topics: Adenine; Central Nervous System Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidines; Pro | 2020 |
Novel agents for primary central nervous system lymphoma: evidence and perspectives.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; L | 2018 |
Introduction of novel agents in the treatment of primary CNS lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; | 2019 |
4 trials available for adenine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Disease-Free Survival; Fe | 2021 |
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Antineoplastic Com | 2019 |
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) net
Topics: Adenine; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; Femal | 2019 |
Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study.
Topics: Adenine; Adult; Antineoplastic Agents; Central Nervous System Neoplasms; Drug Administration Schedul | 2002 |
23 other studies available for adenine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
Topics: Adenine; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma; Lymphoma, B-Cel | 2022 |
[Application of ibrutinib in primary central nervous system lymphoma].
Topics: Adenine; Central Nervous System Neoplasms; Humans; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
Topics: Adenine; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Female; Humans; Lymphoma; Male; | 2020 |
[Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; H | 2020 |
Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocol | 2020 |
Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Prot | 2020 |
[Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
Topics: Adenine; Aged; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Mantle-Ce | 2020 |
Case 6-2021: A 65-Year-Old Man with Eye Pain and Decreased Vision.
Topics: Adenine; Aged; Blood Cell Count; Central Nervous System Neoplasms; Cerebrospinal Fluid; Diagnosis, D | 2021 |
Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Ner | 2021 |
Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction.
Topics: Adenine; Administration, Oral; Central Nervous System Neoplasms; Female; Humans; Hypersensitivity, I | 2021 |
Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
Topics: Adenine; Adult; Central Nervous System Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; L | 2022 |
A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy.
Topics: Adenine; Aged; Brain Diseases; Central Nervous System Neoplasms; Female; Humans; Immunotherapy; Pipe | 2021 |
Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials.
Topics: Adenine; Anilides; Aniline Compounds; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Cell Cy | 2018 |
Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
Topics: Adenine; Central Nervous System Neoplasms; Humans; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging | 2018 |
Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Central Nervous System; Central Nervous System N | 2018 |
Is ibrutinib associated with disseminated cryptococcosis with CNS involvement?
Topics: Adenine; Aged, 80 and over; Central Nervous System Neoplasms; Cryptococcosis; Humans; Male; Piperidi | 2019 |
Standard Dose of Ibrutinib is Effective in the Treatment of Bing-Neel Syndrome.
Topics: Adenine; Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Magnetic Resonance Imaging | 2020 |
Primary CNS lymphoma patient-derived orthotopic xenograft model capture the biological and molecular characteristics of the disease.
Topics: Adenine; Animals; Caudate Nucleus; Central Nervous System Neoplasms; Disease Models, Animal; Heterog | 2019 |
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.
Topics: Adenine; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Ma | 2015 |
Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Central | 2017 |
Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome.
Topics: Adenine; Antineoplastic Agents; Biomarkers; Blood-Brain Barrier; Central Nervous System Neoplasms; H | 2017 |
Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.
Topics: Adenine; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Female; Follow-Up Studies; H | 2017 |
EGFR inhibitor BIBU induces apoptosis and defective autophagy in glioma cells.
Topics: Adenine; Apoptosis; Autophagy; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Central Nervous S | 2013 |